Despite its relative rarity as a clinical entity, gastrointestinal stromal tumor (GIST) has garnered much interest in the past several years. The recognition of KIT activation as essential in the tumorigenesis of GIST and the subsequent treatment of GISTs with a molecular inhibitor of KIT signaling, imatinib mesylate (STI 571, Gleevec; Novartis Pharmaceuticals, Basel, Switzerland), represent landmark achievements in solid tumor oncology. The use of imatinib in the management of GIST most likely signals the beginning of the application of specific molecular and genetic approaches to cancer therapy. Thus, the integration of surgery and targeted therapy in the treatment of GIST, which is currently the subject of much investigation, may serve as a paradigm for the multimodality management of other solid malignancies.
KeywordsChronic Myeloid Leukemia Stromal Tumor National Comprehensive Cancer Network Gastrointestinal Stromal Tumor National Comprehensive Cancer Network
Unable to display preview. Download preview PDF.
- 1.Kindblom LG. Gastrointestinal stromal tumors: diagnosis, epidemiology, prognosis. Presented at ASCO Annual Meeting, Chicago, IL, 2003.Google Scholar
- 6.Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003;6:39–48.PubMedCrossRefGoogle Scholar
- 20.Fletcher JA, Corless CL, Dimitrijevic S, et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2003;22:815.Google Scholar
- 21.Demetri GD, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tryosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 2004;22(14S):3001.Google Scholar
- 22.Desai J, Maki R, Heinrich MC, et al. Activity and tolerability of the multitargeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Presented at 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, 2004.Google Scholar
- 29.Demetri GD, Benjamin R, Blanke CD, et al. Optimal management of patients with gastrointestinal stromal tumors (GIST): expansion and update of NCCN Clinical Practice Guidelines. J Comprehensive Cancer Network 2004;(in press).Google Scholar
- 34.Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 2003;22:814.Google Scholar
- 36.Blanke C, Joensuu H, Demetri G, et al. Long-term follow-up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Presented at 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, 2004.Google Scholar